Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States
This United States (US)-based claims analysis evaluated the real-world safety of tofacitinib versus biologic treatments in patients with psoriatic arthritis (PsA). Risk of serious infections, myocardial infarction (MI) or stroke, venous thromboembolism (VTE), and malignancy (exc…